UBS Group Issues Pessimistic Forecast for Axon Enterprise (NASDAQ:AXON) Stock Price

Axon Enterprise (NASDAQ:AXON) had its price objective lowered by UBS Group from $610.00 to $570.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the biotechnology company’s stock. UBS Group’s target price suggests a potential upside of 3.60% from the company’s current price.

A number of other research firms have also recently commented on AXON. Weiss Ratings reissued a “hold (c-)” rating on shares of Axon Enterprise in a research report on Monday, December 29th. Barclays decreased their price target on Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating for the company in a research note on Wednesday. TD Cowen reaffirmed a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, November 5th. William Blair restated an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 3rd. Finally, Needham & Company LLC dropped their price target on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Sixteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, Axon Enterprise currently has a consensus rating of “Moderate Buy” and a consensus price target of $762.93.

Axon Enterprise Trading Up 5.8%

NASDAQ AXON opened at $550.19 on Wednesday. The stock’s fifty day moving average price is $538.95 and its 200-day moving average price is $627.46. The company has a current ratio of 2.53, a quick ratio of 2.89 and a debt-to-equity ratio of 0.53. The stock has a market cap of $43.42 billion, a P/E ratio of 361.97, a P/E/G ratio of 15.67 and a beta of 1.48. Axon Enterprise has a 12 month low of $396.41 and a 12 month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. The company had revenue of $796.72 million for the quarter, compared to analysts’ expectations of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. Axon Enterprise’s revenue was up 38.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.08 EPS. As a group, equities analysts forecast that Axon Enterprise will post 5.8 EPS for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, President Joshua Isner sold 20,000 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $552.60, for a total value of $11,052,000.00. Following the transaction, the president directly owned 249,502 shares in the company, valued at approximately $137,874,805.20. This trade represents a 7.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $500.24, for a total transaction of $5,002,400.00. Following the transaction, the chief executive officer owned 3,090,997 shares in the company, valued at $1,546,240,339.28. This represents a 0.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 58,040 shares of company stock valued at $32,251,738 in the last quarter. Insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in AXON. Vanguard Group Inc. increased its holdings in Axon Enterprise by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock worth $5,319,928,000 after acquiring an additional 53,060 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Axon Enterprise by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock worth $1,265,657,000 after buying an additional 35,544 shares during the period. Baillie Gifford & Co. increased its stake in Axon Enterprise by 1,198.7% in the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock worth $932,869,000 after buying an additional 1,516,099 shares in the last quarter. Sands Capital Management LLC raised its holdings in Axon Enterprise by 11.6% during the fourth quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock valued at $914,047,000 after acquiring an additional 167,095 shares during the period. Finally, Wellington Management Group LLP lifted its position in shares of Axon Enterprise by 326.9% in the fourth quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock valued at $874,463,000 after acquiring an additional 1,179,038 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise News Summary

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 results materially beat expectations — revenue +39% to ~$796.7M and non‑GAAP EPS $2.15 vs. consensus — and management reiterated aggressive growth targets and large contracted bookings, which drove investor optimism. Axon’s Q4 Earnings Top Estimates
• Positive Sentiment: Company highlighted AI adoption across its device + software platform (body cams, TASER 10, evidence management) and reported strong net revenue retention and bookings/backlog growth — messaging that the hardware‑to‑software flywheel reduces AI disruption risk and supports revenue expansion. Taser Maker Axon Says Its Business Is Being ‘Supercharged by AI.’
• Positive Sentiment: Market reaction: multiple outlets and analysts upgraded tone or reiterated buy cases based on the beat and 2026+ targets, lifting momentum after a prior steep selloff tied to SaaS/AI fears. Taser-maker Axon pops 18% as AI boosts demand
• Neutral Sentiment: Analyst price‑target revisions are mixed: several firms trimmed targets post‑report (Barclays, Morgan Stanley, Piper Sandler) but many maintain overweight/buy views — the market is re‑pricing near‑term risk while keeping upside scenarios. These Analysts Cut Their Forecasts On Axon
• Neutral Sentiment: Short-interest data in the feed appears anomalous (reporting 0 shares / NaN changes) and shows no meaningful days‑to‑cover signal — treat that data as unreliable for trading decisions today.
• Negative Sentiment: An insider transaction: CEO Patrick W. Smith sold 10,000 shares at ~$500.24 (filed with the SEC). The sale is small relative to total holdings but may be viewed negatively by some traders. SEC Form 4
• Negative Sentiment: Profitability caveat: several pieces note that while top‑line growth is accelerating, margins/profitability have not fully caught up — a risk if investors rotate to profitability metrics. Axon Stock Is On Fire, But Here’s the Bad News

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.